Market potentials of robotic systems in medical science: analysis of the Avatera robotic system.
Avatera robotic system
Business modeling
Cost analysis
Da Vinci
Robot-assisted surgery
SWOT analysis
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
24
05
2021
accepted:
04
08
2021
pubmed:
24
8
2021
medline:
19
2
2022
entrez:
23
8
2021
Statut:
ppublish
Résumé
To evaluate the potential opportunities and possible competitiveness of Avatera robotic system (ARS) (Avateramedical, Germany), and perform predictive cost-analysis for its implementation and dissemination. Our study employed a projective quantitative research design. SWOT (strengths, weaknesses, opportunities, threats) analysis was used to map ARS internal competencies towards external contexts, and potential opportunities and risks in the robotic market. The ARS purchase and procedural costs were evaluated in two different scenarios. In the first scenario, setting the purchase cost of the Avatera at around $1.3-1.5 million, a total $400 procedural cost reduction compared to the RAS performed with the da Vinci Xi can be calculated. In the second scenario, with a purchase cos of the ARS of $700.000-800.000 and considering a 5-year period with an annual ARS volume of 500 procedures, only an additional $300 will be attributed to the robot itself. Our projections revealed that for an effective competition the purchase cost of ARS should range between $700.000 and $800.000 during the initial phase of market entry. The marketing strategy of the ARS should be oriented towards countries without any robotic system in operational use, followed by countries where the competition intensity in the marketplace is low. The introduction of new robotic systems will greatly affect and reshape the market of robotic surgery. The ARS has all the technical capacity ensuring the performance of high-quality surgical procedures. A fast spread and implementation of the ARS could be expected should the purchase and maintenance costs be kept low.
Identifiants
pubmed: 34424374
doi: 10.1007/s00345-021-03809-z
pii: 10.1007/s00345-021-03809-z
pmc: PMC8381715
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-289Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
J Endourol. 2020 May;34(5):541-549
pubmed: 32336150
Eur Urol Focus. 2020 Sep 15;6(5):1032-1048
pubmed: 32553544
World J Urol. 2018 Apr;36(4):537-541
pubmed: 29427003
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):430-440
pubmed: 32269329
Nat Rev Urol. 2015 Jan;12(1):55-60
pubmed: 25535000
J Healthc Qual. 2017 Jul/Aug;39(4):211-218
pubmed: 26566237
Isr Med Assoc J. 2015 Sep;17(9):563-6
pubmed: 26625547
APMIS. 2021 Jul;129(7):408-420
pubmed: 33932317
Urologe A. 2020 Sep;59(9):1044-1050
pubmed: 32785733
Arab J Urol. 2019 Apr 23;17(2):106-113
pubmed: 31285921
Arab J Urol. 2018 Aug 07;16(3):270-284
pubmed: 30147957
J Robot Surg. 2021 Apr;15(2):251-258
pubmed: 32537713
J Urol. 2012 Apr;187(4):1392-8
pubmed: 22341274
BJU Int. 2017 Dec;120(6):822-841
pubmed: 28319324
Minerva Urol Nefrol. 2020 Feb;72(1):49-57
pubmed: 31833725